Long-lasting effect of belantamab mafodotin in heavily pretreated multiple myeloma.

Belantamab mafodotin (BLMF) is an interesting therapeutic alternative for multiple myeloma (MM) patients pretreated with immunomodulatory drugs, proteasome inhibitors, and anti-CD38 monoclonal antibodies. Scientific evidence on BLMF provides immature data about progression-free survival and overall survival by short follow-up of patients with poor prognoses. Cases with long follow-ups could provide additional information about BLMF.

Patient benefit as a goal of humanization.

Patient empowerment is one of the main pillars of humanisation. Therefore, consideration of patients' preferences and expectations should be  taken into account during the practice of any healthcare professional.  Improving overall survival and quality of life are the main wishes of patients.

Concordance between expectations and preferences of patients and evaluation criteria of the European Medicines Agency.

Objective: The European Medicines Agency's marketing authorisation criteria  for drugs are reflected in the European Public Assessment Reports. The  objective is to describe the expectations and preferences of our  oncohematological outpatients with respect to their oral treatments, and to  evaluate the concordance with the results of European Public Assessment Reports.

Method: A survey of onco-hematological patients' expectations and preferences about overall survival and quality of life was developed, with three items: expectations on treatment, preferences of benefit and  willingness to receive novel treatments with non-definitive results.

Belantamab mafodotin for relapsed or refractory multiple myeloma.

Refractory multiple myeloma (MM) presents poor responses to therapies. New drugs for highly pretreated MM are a hope for this clinical context with limited treatment options. We developed a comparative commentary on the evidence about the use of belantamab mafodotin in heavily pretreated relapsed or refractory MM with respect to other therapies.

Efficacy of early use of remdesivir: a systematic review of subgroup analysis.

Objective: A possible benefit has been suggested for early treatment of severe coronavirus disease 2019 (COVID-19) with remdesivir. The efficacy of this drug is controversial and could significantly influence the efficiency in healthcare systems. The objective is the methodological interpretation of subgroup analyzes according to starting of remdesivir treatment with respect to symptom onset of COVID-19.

Daratumumab-based therapies in transplant-ineligible patients with untreated multiple myeloma and hepatic dysfunction: A systematic review of subgroup analyses.

Introduction: There is subgroup analysis suggesting a lack of benefit of daratumumab use in multiple myeloma (MM) and hepatic disease (HD). The objectives of this study were to conduct a systematic review and interpretation of daratumumab-based regimen efficacy in transplant-ineligible patients with untreated MM and HD.

Methods: A systematic search in Pubmed database about randomized clinical trials (RCTs) with subgroup analysis regarding hepatic function for overall survival (OS) or progression-free survival (PFS) were developed.

Switching of monoclonal antibodies against calcitonin gene-related peptide in chronic migraine in clinical practice: a case series.

A multicentre case series of patients with chronic migraine (CM) treated with monoclonal antibodies directed against calcitonin gene-related peptide (CGRP-mAbs) switching were developed. The effectiveness and safety of CGRP-mAbs switching as a preventive treatment for CM in clinical practice were recorded. Effectiveness was measured by ≥50% reduction of monthly migraine days in respect to baseline and reduction in pain intensity.

Use of ustekinumab after other biological therapies in moderate-severe psoriasis: Real long-term data.

Objective: Ustekinumab is used in moderate-severe plaque psoriasis with  inadequate response to anti-tumour necrosis factor α drugs. Recent studies  support the need to assess real long-term data. The aim of this study was to  evaluate the real long-term effectiveness and safety of ustekinumab in  moderate-severe plaque psoriasis refractory to 2 anti-tumour necrosis factor α  drugs.

Monoclonal antibodies against calcitonin gene-related peptide in chronic migraine: an adjusted indirect treatment comparison.

Objective: New monoclonal antibodies against the calcitonin generelated peptide pathway have recently been developed for the  prevention of migraine. The aim of this study is to compare the efficacy  of monoclonal antibodies against the calcitonin generelated peptide  pathway drugs in chronic migraine through an adjusted indirect  treatment comparison, and to establish whether they can be considered  equivalent therapeutic alternatives in this pathology.

Method: A bibliographic search of randomized clinical trials was performed in PubMed database on December 26, 2019.